Provexis (PXS) AI Stock Analysis

• Market Cap: £24.63M
• Dividend Yield: N/A
• Average Volume (3M): 766.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: -27.38%
• EPS Growth: -50.00%
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 570,442
• 30 Day Avg. Volume: 766,252
• PEG Ratio: 0.68
• Price to Book (P/B): 7.92
• Price to Sales (P/S): 7.95
• P/FCF Ratio: -30.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: 0.98 p ▼(-7.14% Downside)
• Action: Reiterated
• Date: 03/18/26

Positive Factors

Debt-free balance sheet

Zero reported debt materially reduces refinancing and interest-rate risk, giving management flexibility to pursue licensing deals, R&D or selective commercial investments over the next 2-6 months without near-term leverage constraints. This durability supports survival while revenues scale.

Negative Factors

Persistent negative cash flow

Consistent negative operating and free cash flow requires ongoing funding and raises dilution or financing risk if losses persist. Over a multi-month horizon, continued cash burn can constrain commercial investment and force unfavorable financing decisions that weaken strategic optionality.

Provexis Business Overview & Revenue Model

Company Description

Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique ...

Read more

Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique ...

How the Company Makes Money

Provexis primarily makes money by commercialising its intellectual property and functional-ingredient technologies through business-to-business arrangements rather than by operating as a large-scale consumer brand. Key revenue streams include: (1)...

Read more

Provexis primarily makes money by commercialising its intellectual property and functional-ingredient technologies through business-to-business arrangements rather than by operating as a large-scale consumer brand. Key revenue streams include: (1)...

Provexis Financial Statement Overview

Breakdown	TTM	Sep 2024	Mar 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	871.26K	1.29M	801.96K	389.92K	426.17K	505.33K
Gross Profit	428.97K	532.94K	283.80K	294.42K	380.05K	456.19K
EBITDA	-610.13K	-449.63K	-603.59K	-420.93K	-299.20K	0.00
Net Income	-603.80K	-452.72K	-586.24K	-385.24K	-224.25K	-341.01K
Balance Sheet
Total Assets	841.84K	1.01M	498.04K	845.99K	1.13M	1.29M
Cash, Cash Equivalents and Short-Term Investments	523.35K	708.09K	189.36K	379.12K	863.87K	1.08M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	230.95K	248.21K	307.45K	188.34K	157.91K	150.68K
Stockholders Equity	1.14M	1.30M	724.34K	1.19M	1.50M	1.66M
Cash Flow
Free Cash Flow	-544.53K	-338.90K	-191.50K	-519.85K	-213.79K	-262.32K
Operating Cash Flow	-544.53K	-338.90K	-191.50K	-519.85K	-213.54K	-262.07K
Investing Cash Flow	2.79K	1.93K	1.73K	887.00	78.00	-250.00
Financing Cash Flow	586.89K	857.63K	0.00	35.10K	1.05M	1.05M

Provexis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Neutral. The current price of 1.05 is below the 20-day moving average (MA) of 1.09, below the 50-day MA of 1.16, and below the 200-day MA of 1.06, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.06 is Neutral, neither overbought nor oversold. The STOCH value of 41.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	66 Neutral	£66.40M	30.34	2.55%	0.31%	9.96%	29.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PXS	45 Neutral	£24.63M	-105.00	-49.45%	―	-27.38%	-50.00%
STX	44 Neutral	£58.85M	-7.59	64.57%	―	36.19%	60.75%
CHLL	40 Underperform	£993.56K	>-0.01	233.76%	―	―	―